Kidney Cancer Research

For enrollment information involving the following trials, please contact a member of our research support staff.




A Prospective, Randomized, Controlled, Multi-Center Evaluation of a Powered Vascular Stapler in Laparoscopic Nephrectomies and Nephroureterectomies

Inclusion Criteria:

  • Patients scheduled for a simple or radical laparoscopic nephrectomy or a laparoscopic nephroureterectomy in accordance with the institution's standard of care (SOC)

  • No prior history of partial or wedge nephrectomy (on the kidney in which the procedure will be performed)

  • ECOG status = 0-1

  • ASA score < 3

Exclusion Criteria:

  • Prior chemotherapy or radiation (within 30 days prior to the procedure or the duration of the subject's enrollment)

  • The subject is judged unsuitable for study participation by the investigator for any other reason

  • Physical or psychological condition which would impair study participation; pregnancy

Sponsor: Ethicon Endosurgery

Principal Investigator: Viraj Master, MD, PhD

Co-Investigators & Collaborators: Kenneth Ogan, MD, Mehrdad Alemozaffar, MD, Christopher Filson, MD


Atezolizumanb (Anti-RD-L1 Antibody) as Adjuvant Therapy in Patients with Renal Cell Carcinoma at High Risk of Developing Metastasis Following Nephrectomy

Inclusion Criteria:

  • Pathologically confirmed RCC with a component of either clear cell histology or sarcomatoid histology (sarcomatoid differentiation regardless of the primary epithelial subtype) that has not been previously treated in the adjuvant or neoadjuvant setting

  • Patients with localized disease with T2 Grade 4, T3a Grade 3 – 4, T3b/c any grade, T4 any grade, and TxN + any grade are eligible

  • Absence of residual disease and absence of metastasis, as confirmed by a negative baseline computed tomography (CT) of the pelvis, abdomen, and chest no more than four weeks prior to randomization

  • Radical or partial nephrectomy with lymphadenectomy in select patients; must have negative surgical margin

  • ECOG performance status of ≤1

Exclusion Criteria

  • Malignancies other than RCC within five years prior to Cycle 1, Day 1 (exclusions apply, please check study protocol)

  • Bilateral synchronous tumors with inheritable forms of RCC, including von Hippel-Lindau

  • Any approved anti-cancer therapy, including chemotherapy or hormonal therapy, within three weeks prior to initiation of study treatment. Treatment with any other investigational agent or participation in another clinical study

  • CNS metastases or leptomeningeal disease

Principal Investigator: Viraj Master, MD, PhD

Co-Investigators & Collaborators: Mehmet Bilen, MD (Department of Hematology and Medical Oncology), Mehrdad Alemozaffar, MD, Kenneth Ogan, MD

««return to top